FDA Issues Early Alert On Abiomed Heart Pump Controller Purge Cassette Issue
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-heart-pump-controller-purge-cassette-issue-abiomed
Read original at benzingaStocks · News reference
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
Johnson & Johnson secures FDA clearance for MONARCH QUEST 3 software, boosting robotic bronchoscopy accuracy with AI. new 3D imaging tools.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 5:10 PM
- Checked
- Aug 19, 2026, 5:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.
Read original at globenewswire-incIntravascular Lithotripsy Market Size to Reach USD 4.19 Billion by 2035 as Coronary and Peripheral IVL Adoption Accelerates – SNS Insider
The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.
Read original at globenewswire-incJohnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
Read original at benzinga